Q2 EPS Estimate for Galectin Therapeutics Raised by Analyst

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - HC Wainwright boosted their Q2 2025 earnings estimates for shares of Galectin Therapeutics in a research note issued to investors on Wednesday, April 2nd. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($0.19) per share for the quarter, up from their prior forecast of ($0.21). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($1.06) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03).

Separately, StockNews.com cut shares of Galectin Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, December 30th.

Remove Ads

Galectin Therapeutics Trading Up 4.7 %

NASDAQ:GALT traded up $0.06 during midday trading on Monday, hitting $1.35. 192,253 shares of the company traded hands, compared to its average volume of 318,846. The firm has a market capitalization of $85.29 million, a P/E ratio of -1.85 and a beta of 0.79. The firm's fifty day moving average is $1.47 and its 200-day moving average is $1.87. Galectin Therapeutics has a 12-month low of $0.73 and a 12-month high of $4.27.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. State Street Corp lifted its stake in shares of Galectin Therapeutics by 9.3% during the 3rd quarter. State Street Corp now owns 251,014 shares of the company's stock worth $690,000 after acquiring an additional 21,399 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new stake in Galectin Therapeutics in the third quarter worth $117,000. Barclays PLC lifted its position in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company's stock worth $79,000 after purchasing an additional 21,598 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Galectin Therapeutics by 2.5% during the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company's stock valued at $2,372,000 after purchasing an additional 20,817 shares during the period. Finally, Soltis Investment Advisors LLC bought a new position in shares of Galectin Therapeutics in the third quarter worth about $387,000. Hedge funds and other institutional investors own 11.68% of the company's stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.